Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daré Bioscience ( (DARE) ) has provided an update.
On March 2, 2026, Daré Bioscience, Inc. made an updated corporate presentation available to investors through the investors section of its website, providing refreshed information on the company for the market. The presentation was simultaneously furnished to regulators as a supplemental disclosure, signaling an effort to keep shareholders and potential investors current on Daré’s strategy and operations through non‑filed investor materials.
Because the materials are being furnished rather than formally filed, they are not subject to certain legal liability provisions under U.S. securities law and will not automatically be incorporated into the company’s other securities filings. This approach underscores that the update is intended as an informational resource for stakeholders rather than a change to the company’s formal reporting framework.
The most recent analyst rating on (DARE) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.
The score is held down primarily by weak financial performance (minimal/declining revenue, ongoing losses, and TTM cash burn) and only modest technical strength (below key moving averages). These are partially offset by a relatively positive earnings call focused on upcoming product launches and a grant-supported pipeline, plus supportive financing and strategic control developments from recent corporate events.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Daré Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing products in women’s health. The company typically targets areas such as contraception, fertility, and other gynecologic and reproductive health conditions, aiming to address unmet medical needs in these specialized markets.
Average Trading Volume: 157,243
Technical Sentiment Signal: Strong Sell
Current Market Cap: $24.29M
Learn more about DARE stock on TipRanks’ Stock Analysis page.